Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946486 | 0.87 | — | — | |
| SCHEMBL10863275 | 0.86 | DNM1 (0.32) | — | |
| SCHEMBL572712 | 0.83 | — | — | |
| SCHEMBL20589984 | 0.83 | — | — | |
| SCHEMBL16742365 | 0.81 | ALDH1A1 (0.36) | LMNA | |
| SCHEMBL14811181 | 0.81 | — | — | |
| SCHEMBL20602876 | 0.81 | CA2 (0.32) | — | |
| SCHEMBL9654838 | 0.81 | HSD17B10 (0.41) | — | |
| SCHEMBL1533956 | 0.81 | — | — | |
| SCHEMBL2724810 | 0.81 | CA2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3395876-B1 | NOVEL NANOPARTICLES | COVESTRO NETHERLANDS BV (NL) | 2024-07-31 | — | — | EP | disclosed |
| EP-3483638-B1 | CORE-SHELL NANOPARTICLES | COVESTRO NETHERLANDS BV (NL) | 2021-10-27 | — | — | EP | disclosed |
| CN-113444294-A | Preparation method of oxidized chitosan/N, O-carboxymethyl chitosan nanoparticles | 苏州市德赫亚新纺织科技有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-105969022-B | Core-shell nanoparticles | 帝斯曼知识产权资产管理有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200230069-A1 | CORE-SHELL NANOPARTICLES | COVESTRO (NETHERLANDS) B.V. (NL) | 2020-07-23 | — | — | US | disclosed |
| EP-2059836-B1 | COATING COMPOSITION COMPRISING CORE-SHELL NANOPARTICLES | DSM IP ASSETS BV (NL) | 2019-10-23 | — | — | EP | disclosed |
| EP-3483638-A1 | CORE-SHELL NANOPARTICLES | DSM IP Assets B.V. (NL) | 2019-05-15 | — | — | EP | disclosed |
| EP-3395876-A1 | NOVEL NANOPARTICLES | DSM IP Assets B.V. (NL) | 2018-10-31 | — | — | EP | disclosed |
| EP-2059558-B1 | NOVEL NANOPARTICLES | DSM IP ASSETS BV (NL) | 2018-10-24 | — | — | EP | disclosed |
| US-20180078509-A1 | CORE-SHELL NANOPARTICLES | DSM IP ASSETS BV (NL) | 2018-03-22 | — | — | US | disclosed |
| US-20100009001-A1 | NOVEL NANOPARTICLES | DSM IP ASSETS B.V. (NL) | 2010-01-14 | — | — | US | disclosed |
| EP-1868653-A2 | HMGCOA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF | PSivida Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070112050-A1 | HMGCoA reductase inhibitor combinations and uses thereof | PSIVIDA INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2006110882-A2 | HMGCOA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF | PSIVIDA INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-0785920-B1 | MULTIFUNCTIONAL CROSS-LINKING REAGENTS FOR HEMOGLOBIN, AND CROSS-LINKED HEMOGLOBIN CONJUGATES | KLUGER RONALD (CA) | 2000-05-17 | — | — | EP | disclosed |
| US-5811521-A | Multifunctional crosslinking reagents for hemoglobin, and crosslinked hemoglobin conjugates | KLUGER RONALD H (CA) | 1998-09-22 | — | — | US | disclosed |
| EP-0785920-A1 | MULTIFUNCTIONAL CROSS-LINKING REAGENTS FOR HEMOGLOBIN, AND CROSS-LINKED HEMOGLOBIN CONJUGATES | KLUGER, Ronald (CA) | 1997-07-30 | — | — | EP | disclosed |
| WO-1997000236-A1 | MULTIFUNCTIONAL CROSS-LINKING REAGENTS FOR HEMOGLOBIN, AND CROSS-LINKED HEMOGLOBIN CONJUGATES | KLUGER RONALD (CA) | 1997-01-03 | — | — | WO | disclosed |
| US-4687844-A | Process for the direct preparation of N,N-disubstituted derivatives for 4,13-diaza-18-crown-6 | UNIVERSITY OF MARYLAND (US) | 1987-08-18 | — | — | US | disclosed |
| US-4597903-A | Process for the direct preparation of N,N-disubstituted derivatives for 4,13-diaza-18-crown-6 | UNIVERSITY OF MARYLAND (US) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112050-A1 | HMGCoA reductase inhibitor combinations and uses thereof | HMGCR, HMGB2, HMGB3 | LMNA 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.